Bayer To Split Off Consumer Or Crop Science, Or Both, Or Neither

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

After a miserable third quarter the German group is cutting jobs and considering splitting up, but concrete decisions are thin on the ground.  

Bayer logo

Bayer AG has hemorrhaged both earnings and value this year, and management has decided that only extreme measures can save the group. It has ruled out a simultaneous three-way split, but might do a staggered one. Or it might just hive off its crop science division. Or its consumer health unit. Or it might stay as it is.

Key Takeaways

  • Bayer flipped from a net profit in Q3 2022 to a sizeable net loss last quarter

The only definite plan the group has mustered is that it will restructure, stripping out layers of management to speed...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.